Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
about
From prolonging life to prolonging working life: Tackling unemployment among liver-transplant recipientsEffect of rifaximin on gut microbiota composition in advanced liver disease and its complicationsThe enteric microbiome in hepatobiliary health and diseaseMarkers of bacterial translocation in end-stage liver diseaseThe conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosisAntibiotics for the treatment of hepatic encephalopathySafety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathyPathogenesis, diagnosis, and treatment of hepatic encephalopathy.The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy.Minimal hepatic encephalopathyRifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.Diagnosis of covert hepatic encephalopathy without specialized tests.Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.A survey of patterns of practice and perception of minimal hepatic encephalopathy: a nationwide survey in IndiaLipid profile is associated with the incidence of cognitive dysfunction in viral cirrhotic patients: A data-mining analysis.Structural and functional abnormalities of default mode network in minimal hepatic encephalopathy: a study combining DTI and fMRI.Altered effective connectivity network of the basal ganglia in low-grade hepatic encephalopathy: a resting-state fMRI study with Granger causality analysis.Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathyThe gut microbiota and the liver: implications for clinical practice.Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalizationMinimal hepatic encephalopathy impairs quality of life.The diagnosis and treatment of minimal hepatic encephalopathyDiagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.Alzheimer's disease and gut microbiota.Covert and Overt Hepatic Encephalopathy: Diagnosis and ManagementUpdate on the management of cirrhosis - focus on cost-effective preventative strategiesHow to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist.Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China.Meta-analysis: The diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy.Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes.Rifaximin in the treatment of hepatic encephalopathy.Inhibitory control test for the detection of minimal hepatic encephalopathy in patients with cirrhosis of liver.Brain perfusion single photon emission computed tomography abnormalities in patients with minimal hepatic encephalopathy.Driving simulation can improve insight into impaired driving skills in cirrhosis.PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis.New therapeutic paradigm for patients with cirrhosis.Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications.Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?Disaccharides in the treatment of hepatic encephalopathy.
P2860
Q26748600-19DCCD24-4C27-4DBC-8538-E6049F6A2CEBQ26775927-37927076-CDE6-4F62-94D4-3D07B35498D0Q26777426-0B3840EB-2426-4BDB-B7C8-76348667BD54Q26783888-D238DC79-2073-487F-AFD9-2F258E786E6CQ27009164-0A651515-3B61-487A-90EB-46AACC96EDE1Q27012878-195586FF-4A14-426A-B53A-347812DE0B33Q28236913-39E13FCC-B366-42CB-8DB0-04F802EB2AB4Q30907818-B65A007B-93E3-4DFB-BD9A-A9183571DAEAQ33439413-8B24C1A5-B960-4E4C-AD6B-14388B5FD0DBQ33440095-132F52B4-9FC0-472C-8473-C563857FC83EQ33465655-AAE4C2FC-7026-4BC3-AF46-41C2360F3136Q33779392-DBF69EA6-EC91-438B-B5A6-808743DAB838Q34135613-EEA9370D-8A38-4DC1-9141-BD4683D7D5ABQ34335298-3185FA87-D816-4EF4-AC14-0AEC0E6AC3B0Q34375500-329E0133-58CC-4FE0-AEE9-CFDA97D2B48AQ34387875-752EAB13-F4DB-4BAC-8864-A057B95FB8DAQ34551662-73399709-5959-4BE3-9DC7-18C2C5F66C02Q34658087-60EEE94E-6B5B-4F91-A3DE-99C2817804B3Q35019661-F4E5C287-2F14-456C-A09C-D07EE4F00A12Q35064105-7297A6B1-D482-4CB7-B3F5-598FF1AC949DQ35642834-67B4CF75-D844-447B-AA16-50F4B157FA27Q35865294-42F6BD4A-4EE1-4E37-9ACB-1A7B7E952871Q35870131-E8DDAD94-F55F-4BF1-83E2-8514619D56E2Q35939710-1CBF961A-96D2-4116-B0A4-5ABE69681660Q36114884-C079F631-AC4A-4EF5-9A1E-109392175661Q36199772-70343DCD-FBC6-4721-8151-D2324D182EF0Q36784836-58DDD98E-60A1-4074-9238-FC80A38097F0Q36947936-A9C571C0-00E8-4B4A-8997-61BF9F549BE5Q37087534-EB568F2C-89FA-4370-A0C9-BB3EF29EAA82Q37142443-3C1AE85D-4C4B-4374-BE37-CDCF6C107413Q37353473-4A833631-4C30-4AC3-AEAA-659CED09B8AAQ37355818-321FAB67-DDD0-470A-949C-E18809DC2734Q37613252-C1762591-D1F5-4648-89EF-2E3D05A041AFQ37613911-EE84A6C9-D3E3-4840-B70B-53755A142917Q37677018-09BA550B-2820-40A4-8EF7-89761361D0D1Q37706741-1685932E-C461-4265-8695-F924B00E53B3Q38021413-B40D734C-1358-4C5A-AAB8-6B4962071E9CQ38057416-50DB4947-8916-49C5-B749-B18A45D0B6FBQ38070363-D4695C5B-78BB-43BC-A8AE-8E8E345DD318Q38086120-4F88D408-652A-4D2D-AFE7-2421C9507F4F
P2860
Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Rifaximin improves psychometri ...... cephalopathy (the RIME Trial).
@en
Rifaximin improves psychometri ...... minimal hepatic encephalopathy
@nl
type
label
Rifaximin improves psychometri ...... cephalopathy (the RIME Trial).
@en
Rifaximin improves psychometri ...... minimal hepatic encephalopathy
@nl
prefLabel
Rifaximin improves psychometri ...... cephalopathy (the RIME Trial).
@en
Rifaximin improves psychometri ...... minimal hepatic encephalopathy
@nl
P2093
P356
P1476
Rifaximin improves psychometri ...... cephalopathy (the RIME Trial).
@en
P2093
Bholeshwar Prashad Mishra
Omesh Goyal
Rajoo Singh Chhina
Ravinder Kumar Soni
Sandeep Singh Sidhu
P304
P356
10.1038/AJG.2010.455
P407
P577
2010-12-14T00:00:00Z